Arthurian life sciences statement on reneuron stroke study results

Arthurian Life Sciences today welcomed the ‘highly encouraging’ findings of a significant clinical trial by ReNeuron, a global leader in the development of cell-based therapeutics.

The PISCES II trial monitored improvement in arm movement as measured by the ARAT sub-test number two.
The aim was to achieve discernible change within three months in two of the 21 patients receiving treatment. Three patients registered improvement over a variety of timescales. 15 patients in the 21-person study had a “clinically significant response” on at least one of the three commonly-used scales for assessing improvements following treatment.

2017-04-07T10:26:40+00:00 December 5th, 2016|News|